Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs Enveric Biosciences, Inc. (ENVB)

Alzamend Neuro, Inc. and Enveric Biosciences, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and Enveric Biosciences, Inc. are of similar size ($6.2M and $6.2M). Across the 9 metrics below, Alzamend Neuro, Inc. leads on 6 and Enveric Biosciences, Inc. on 3.

Valuation

Metric ALZN ENVB Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.16 9.71
P/B 1.02 0.68 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.15 0.29 0.64
EV/Sales n/m (0.07) 9.21
Earnings yield (174.24%) (481.51%) (33.15%)
Free cash flow yield (120.83%) (193.82%) (25.50%)

Profitability

Metric ALZN ENVB Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) (235.48%) (56.36%)
Return on assets (122.36%) (193.53%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN ENVB Biotechnology median
Revenue growth (TTM) — (13.93%) 6.02%
EPS growth (last fiscal year) 76.77% 84.14% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN ENVB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 10.21 4.72
Net debt to EBITDA 0.08 0.55 0.96

Dividend

Metric ALZN ENVB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALZN ENVB Biotechnology median
Market cap 6.17m 6.22m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack